TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Stock
Certificat
DE000SD7FP67
| Delayed Deutsche Boerse AG 02:46:19 2024-06-14 am EDT | ||
| 19.98 EUR | +0.05% |
|
| Current month | +8.83% | ||
| 1 month | +10.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 19.98 | +0.05% |
| 24-06-13 | 19.97 | -0.55% |
| 24-06-12 | 20.08 | +1.06% |
| 24-06-11 | 19.87 | -1.83% |
| 24-06-10 | 20.24 | +1.00% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 02:46 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SD7FP6 |
| ISIN | DE000SD7FP67 |
| Date issued | 2021-04-08 |
| Strike | 242.7 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.26 € |
|---|---|
| Lowest since issue | 0.053 € |
| Spread | 0.01 € |
| Spread % | 0.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
979.7
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.13%
- Stock Market
- Certificates
- Certificat
